The development of the group’s Medical Imaging equipment business achieved a significant milestone with the announced FDA 510(k) approval of Adaptix orthopaedic 3D imaging product. Their product is potentially transformative for the orthopaedic market with significant advantages over traditional 2D x-ray and CT images. The approval opens the door to the huge potential market in the US. We maintain our expectations and conservative 575p target price. The shares have significant upside potential, ....
